<DOC>
	<DOCNO>NCT01232920</DOCNO>
	<brief_summary>The propose study mask trial , stratify block randomization site , design determine treatment , methotrexate mycophenolate mofetil , effective first-line steroid-sparing treatment patient non-infectious uveitis require corticosteroid-sparing therapy . One hundred non-infectious uveitis patient need corticosteroid-sparing therapy randomize receive either oral methotrexate oral mycophenolate mofetil Aravind Eye Hospitals ( Madurai Coimbatore , South India ) . They follow monthly 6 month enrollment treatment failure . The investigator hypothesize proportion achieve corticosteroid-sparing success 6 month patient take mycophenolate mofetil improve comparison patient take methotrexate .</brief_summary>
	<brief_title>First-line Antimetabolites Steroid-sparing Treatment Uveitis Pilot Trial</brief_title>
	<detailed_description>Uveitis , set condition define intraocular inflammation , significant cause vision loss morbidity United States world . The incidence recently estimate 50 case per 100,000 person-years , prevalence approximately 115 per 100,000 person . Additionally , uveitis believe cause 10 % case legal blindness United States , approximately 30,000 new case blindness per year . In contrast common age-related eye disorder , uveitis may stronger socio-economic impact disproportionately affect young working-age patient . Although etiology uveitis vary , case presume immune-mediated lack know infectious cause . Even develop country India large burden infection , vast majority case non-infectious . The current mainstay treatment noninfectious uveitis corticosteroid ( topical , systemic , locally inject , corticosteroid-eluting implant ) . Due well document local systemic side effect associate corticosteroid therapy , immunosuppressive therapy frequently use corticosteroid-sparing agent patient need long-term therapy . These include antimetabolite , calcineurin inhibitor , alkylating agent , biologic drug . Cost morbidity associate uncontrolled inflammation make selection effective initial steroid-sparing agent extremely important . It common practice patient require steroid-sparing agent treat first less expensive methotrexate switch mycophenolate mofetil event treatment failure . However , result non-comparative retrospective case series indicate uveitis patient may much likely achieve control inflammation tolerate treatment mycophenolate mofetil . Furthermore , approximately half patient fail treatment methotrexate go successful treatment mycophenolate mofetil . There prospective randomized , control trial systematically determine antimetabolite clinically efficacious initial corticosteroid-sparing therapy , make difficult clinician make inform , evidence-based decision first-line immunosuppressive treatment . Our contribution expect definitive understanding comparative efficacy , tolerability , quality life two antimetabolites initial steroid-sparing therapy uveitis patient require chronic therapy . This contribution significant enable clinician make evidence-based decision prescribe first-line immunosuppressive therapy uveitis patient . The use optimal first-line therapy improve quality life reduce risk vision loss complication associate uncontrolled ocular inflammation long-term corticosteroid use .</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Antimetabolites</mesh_term>
	<criteria>Noninfectious anterior , intermediate , posterior panuveitis Active uveitis within last 60 day ( define presence follow accord SUN criterion : ≥ 1+ anterior chamber cell , anterior vitreous cell , vitreous haze , active retinal choroidal lesion ) Prednisone dose ≥ 15 mg/day History corticosteroid taper failure ( inability taper prednisone 10 mg less ) obvious chronic disease necessitate corticosteroidsparing immunosuppressive treatment Any infectious cause uveitis Tuberculosis : Evidence active TB ( PPD CXR require latent TB patient still eligible ) Positive Hepatitis : HBsAg and/or Hep C antibody Positive Syphilis : RPR/VDRL and/or FTAABS Abnormal CBC ( &lt; 2500 WBC &lt; 75,000 Plts &lt; 10 Hgb ) Abnormal liver and/or kidney test ( ALT/AST &gt; 2x normal CR &gt; 1.5 ) Pregnancy breastfeed ( blood urine pregnancy test female , exclude postmenopausal ) Chronic hypotony ( IOP &lt; 5 mm Hg &gt; 3 month ) Prior use immunosuppressive drug treatment uveitis past 6 month Prior fail treatment methotrexate mycophenolate mofetil Periocular intravitreal corticosteroid injection past 3 month Fluocinolone acetonide implant surgery either eye &lt; 3 year Intraocular surgery &lt; 30 day , ocular surgery schedule 6month study period VA hand motion worse good eye &lt; 16 year age enrollment</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>uveitis</keyword>
	<keyword>antimetabolite</keyword>
	<keyword>immunosuppressive</keyword>
	<keyword>clinical trial</keyword>
</DOC>